ACML
MCID: ATY042
MIFTS: 53

Atypical Chronic Myeloid Leukemia (ACML)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 60 30 6 15
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 45 74
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Myeloid Leukemia 60
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

60
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060597
MeSH 45 D054438
NCIt 51 C3176 C3519
ICD10 34 C92.2 C92.20
MESH via Orphanet 46 D054438
ICD10 via Orphanet 35 C92.2
UMLS via Orphanet 75 C0349640 C1292772
Orphanet 60 ORPHA98824
UMLS 74 C1292772

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as leukemia, myeloid, chronic, atypical, bcr-abl negative, is related to myelodysplastic myeloproliferative cancer and myeloid leukemia. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Cytarabine and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 31.0 SETBP1 JAK2 CSF3R ASXL1 ABL1
2 myeloid leukemia 31.0 JAK2 CSF3R ABL1
3 leukemia, chronic myeloid 30.0 SETBP1 PDGFRB PDGFRA JAK2 FGFR1 CSF3R
4 chronic neutrophilic leukemia 30.0 SETBP1 CSF3R ASXL1
5 chronic myelomonocytic leukemia 29.3 SETBP1 PDGFRB JAK2 CSF3R ASXL1
6 leukemia, acute myeloid 28.9 SETBP1 JAK2 CSF3R ASXL1 ABL1
7 myeloproliferative neoplasm 28.4 PDGFRB PDGFRA JAK2 FGFR1 ABL1
8 subacute myeloid leukemia 12.6
9 leukemia 10.8
10 pdgfrb-associated chronic eosinophilic leukemia 10.3
11 sm-ahnmd 10.1 PDGFRA ASXL1
12 acute erythroid leukemia 10.1 PCM1 JAK2
13 hematopoietic stem cell transplantation 10.0
14 cellular neurofibroma 10.0 PDGFRB ABL1
15 desmoid tumor 10.0 PDGFRB PDGFRA
16 hypereosinophilic syndrome, idiopathic 10.0 PDGFRB PDGFRA
17 splenomegaly 10.0 SETBP1 JAK2
18 refractory anemia 10.0 JAK2 ASXL1
19 heart sarcoma 10.0 PDGFRB PDGFRA
20 neutrophilia, hereditary 10.0 JAK2 CSF3R
21 corneal dystrophy, subepithelial mucinous 10.0 PDGFRB PDGFRA
22 spinal chordoma 9.9 PDGFRB PDGFRA
23 thyroid cancer, nonmedullary, 1 9.9
24 pulmonary alveolar proteinosis 9.9
25 thyroid cancer 9.9
26 pneumonia 9.9
27 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9
28 tetrasomy 21 9.9
29 fibrosarcoma of bone 9.9 PDGFRB PDGFRA
30 primary polycythemia 9.8 JAK2 ASXL1 ABL1
31 essential thrombocythemia 9.8 JAK2 ASXL1 ABL1
32 gastrointestinal stromal tumor 9.8 PDGFRB PDGFRA ABL1
33 8p11 myeloproliferative syndrome 9.7 PDGFRB FGFR1
34 lymphoblastic leukemia, acute, with lymphomatous features 9.6 JAK2 FGFR1 ABL1
35 primary hypereosinophilic syndrome 9.6 PDGFRB PDGFRA FGFR1
36 thrombocytopenia-absent radius syndrome 9.6 JAK2 FGFR1
37 chronic leukemia 9.6 SETBP1 JAK2 CSF3R ASXL1
38 juvenile myelomonocytic leukemia 9.6 SETBP1 PDGFRB PDGFRA JAK2
39 polycythemia vera 9.5 PDGFRB PDGFRA JAK2 ABL1
40 chronic eosinophilic leukemia 9.4 PDGFRB PDGFRA FGFR1 ABL1
41 hypereosinophilic syndrome 9.4 PDGFRB PDGFRA FGFR1 ABL1
42 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.3 PDGFRB PDGFRA JAK2 FGFR1
43 glioma 9.2 PDGFRB PDGFRA FGFR1
44 systemic mastocytosis 9.1 PDGFRB PDGFRA JAK2 FGFR1 ASXL1
45 myelodysplastic syndrome 9.0 SETBP1 PDGFRB JAK2 CSF3R ASXL1 ABL1
46 hematologic cancer 9.0 PDGFRB JAK2 FGFR1 CSF3R ABL1
47 bone marrow cancer 8.8 PDGFRB PDGFRA JAK2 FGFR1 CSF3R ABL1

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

27 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.22 PDGFRA
2 Decreased viability GR00221-A-1 10.22 ABL1 PDGFRA PDGFRB FGFR1
3 Decreased viability GR00221-A-2 10.22 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.22 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.22 PDGFRA PDGFRB
6 Decreased viability GR00342-S-1 10.22 ABL1 PDGFRB
7 Decreased viability GR00342-S-2 10.22 ABL1
8 Decreased viability GR00342-S-3 10.22 ABL1
9 Decreased viability GR00402-S-2 10.22 ABL1 PDGFRA PDGFRB FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.74 CSF3R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.74 SETBP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.74 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.74 PDGFRA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.74 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.74 CSF3R PDGFRA SETBP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.74 SETBP1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.74 CSF3R SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 SETBP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.74 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.74 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.74 SETBP1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.74 CSF3R
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.74 PDGFRA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 PDGFRA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 PDGFRA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.74 CSF3R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.74 PDGFRA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.74 PDGFRA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.74 SETBP1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.74 SETBP1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.74 SETBP1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.98 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
2 craniofacial MP:0005382 9.8 ABL1 ASXL1 FGFR1 PDGFRA PDGFRB
3 endocrine/exocrine gland MP:0005379 9.8 ABL1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB
4 hematopoietic system MP:0005397 9.8 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
5 digestive/alimentary MP:0005381 9.77 ABL1 ASXL1 FGFR1 PDGFRA PDGFRB
6 immune system MP:0005387 9.7 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
7 mortality/aging MP:0010768 9.56 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
8 skeleton MP:0005390 9.1 ABL1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
2
Mercaptopurine Approved Phase 3 50-44-2 667490
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
4
Idarubicin Approved Phase 3 58957-92-9 42890
5
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
6
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
7
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
8
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
11
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
12
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
16
Carboplatin Approved Phase 2, Phase 3 41575-94-4 38904 10339178 498142
17
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
18
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
19
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
20
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
21
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
22
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
26
Thioguanine Approved Phase 3 154-42-7 2723601
27
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
28
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
29 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
34 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
37 Interferon-alpha Phase 3,Phase 2
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
40 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 interferons Phase 3,Phase 2
47 Anesthetics Phase 3
48 Excitatory Amino Acid Antagonists Phase 3
49 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
50 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
7 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
8 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
9 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
12 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
13 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
15 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
19 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Recruiting NCT02092324 Phase 2 Ruxolitinib Phosphate
25 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
26 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
27 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Active, not recruiting NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
28 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
29 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
30 Aflibercept in Treating Patients With Myelodysplastic Syndromes Terminated NCT00509249 Phase 2
31 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
32 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
33 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
34 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
35 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Recruiting NCT03289910 Phase 2 Carboplatin;Topotecan Hydrochloride;Veliparib
36 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
37 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
38 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
39 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
40 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
41 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
42 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
43 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
44 Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Terminated NCT00002778 Phase 2
45 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
46 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
47 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
48 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
49 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
50 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Genetic tests related to Atypical Chronic Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Atypical Chronic Myeloid Leukemia 30

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

42
Myeloid, Bone, Bone Marrow, Neutrophil, Liver, Eye, Breast

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show top 50) (show all 65)
# Title Authors Year
1
Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. ( 30635983 )
2019
2
Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia. ( 30899476 )
2019
3
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
4
A typical atypical chronic myeloid leukemia. ( 29744086 )
2018
5
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. ( 29455651 )
2018
6
Atypical chronic myeloid leukemia: a rare entity with management challenges. ( 29226717 )
2018
7
Current and evolving understanding of atypical chronic myeloid leukemia. ( 30078497 )
2018
8
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. ( 30458320 )
2018
9
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. ( 29227326 )
2017
10
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. ( 28314085 )
2017
11
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
12
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. ( 28927137 )
2017
13
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. ( 29025591 )
2017
14
Atypical chronic myeloid leukemia in a German Shepherd Dog. ( 28205462 )
2017
15
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. ( 27853001 )
2016
16
Activity of single-agent decitabine in atypical chronic myeloid leukemia. ( 26378157 )
2016
17
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. ( 26870268 )
2016
18
How I treat atypical chronic myeloid leukemia. ( 27899359 )
2016
19
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. ( 28666496 )
2016
20
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. ( 26274939 )
2016
21
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
22
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. ( 25426665 )
2015
23
Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor A9 rearrangement. ( 26881541 )
2015
24
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. ( 26870618 )
2015
25
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. ( 25343957 )
2015
26
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25491280 )
2015
27
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. ( 26017341 )
2015
28
Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. ( 24991718 )
2015
29
Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25821085 )
2015
30
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
31
Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1. ( 25012564 )
2014
32
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
33
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. ( 25180155 )
2014
34
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
35
A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. ( 23432689 )
2013
36
Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. ( 23904814 )
2013
37
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. ( 23222956 )
2013
38
Atypical chronic myeloid leukemia harboring NUP98-HOXA9. ( 23754767 )
2013
39
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia. ( 23264127 )
2013
40
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. ( 22289493 )
2012
41
Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. ( 21707937 )
2012
42
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. ( 19168282 )
2009
43
JAK2 mutation and atypical chronic myeloid leukemia. ( 19427035 )
2009
44
The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. ( 19500135 )
2009
45
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ( 18555525 )
2008
46
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. ( 17764812 )
2007
47
A case of leukemic pleural infiltration in atypical chronic myeloid leukemia. ( 17043433 )
2006
48
Identification of risk factors in atypical chronic myeloid leukemia. ( 17043019 )
2006
49
A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia. ( 15860363 )
2005
50
Two clonal occurrences of tetrasomy 21 in an atypical chronic myeloid leukemia with wild-type RUNX1 alleles. Additional support for a gene dosage effect of chromosome 21 or RUNX1 in leukemia. ( 15339695 )
2004

Variations for Atypical Chronic Myeloid Leukemia

ClinVar genetic disease variations for Atypical Chronic Myeloid Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FLT3; MYO18A t(13;17)(q12.2;q11.2) Translocation Likely pathogenic GRCh37 Chromosome 13, 28608270: 28608271
2 FLT3; MYO18A t(13;17)(q12.2;q11.2) Translocation Likely pathogenic GRCh37 Chromosome 17, 27423778: 27423779

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

Pathways related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 ABL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
2
Show member pathways
13.24 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
3
Show member pathways
13.16 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
4
Show member pathways
13.11 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
5
Show member pathways
13.04 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
6
Show member pathways
12.81 FGFR1 JAK2 PDGFRA PDGFRB
7
Show member pathways
12.71 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
8
Show member pathways
12.63 FGFR1 JAK2 PDGFRA PDGFRB
9
Show member pathways
12.63 ABL1 FGFR1 PDGFRA PDGFRB
10
Show member pathways
12.49 ABL1 FGFR1 PDGFRA PDGFRB
11
Show member pathways
12.46 FGFR1 JAK2 PDGFRA PDGFRB
12 12.29 ABL1 PDGFRA PDGFRB
13
Show member pathways
12.27 FGFR1 PDGFRA PDGFRB
14
Show member pathways
12.21 FGFR1 PDGFRA PDGFRB
15 12.16 ABL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
16
Show member pathways
12.03 ABL1 FGFR1 PDGFRA PDGFRB
17
Show member pathways
11.92 ABL1 CSF3R JAK2 PDGFRA PDGFRB
18
Show member pathways
11.89 CSF3R FGFR1 PDGFRA PDGFRB
19 11.71 CSF3R FGFR1 PDGFRA PDGFRB
20 11.66 ABL1 CSF3R JAK2
21 11.64 FGFR1 PDGFRA PDGFRB
22
Show member pathways
11.56 ABL1 PDGFRA PDGFRB
23 11.51 FGFR1 PDGFRA PDGFRB
24 11.45 FGFR1 PDGFRA PDGFRB
25 11.39 ABL1 PDGFRB
26 11.35 JAK2 PDGFRB
27 11.2 FGFR1 PDGFRA PDGFRB
28 11.19 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
29 11.13 FGFR1 PDGFRA PDGFRB
30 11.11 FGFR1 JAK2 PDGFRA PDGFRB
31 10.96 PDGFRA PDGFRB
32 10.7 PDGFRA PDGFRB

GO Terms for Atypical Chronic Myeloid Leukemia

Cellular components related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic component of plasma membrane GO:0031226 8.96 PDGFRA PDGFRB
2 receptor complex GO:0043235 8.92 CSF3R FGFR1 PDGFRA PDGFRB

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 FGFR1 JAK2 PDGFRA PDGFRB
2 phosphorylation GO:0016310 9.92 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
3 protein phosphorylation GO:0006468 9.91 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
4 positive regulation of cell migration GO:0030335 9.81 JAK2 PDGFRA PDGFRB
5 cell migration GO:0016477 9.8 FGFR1 PDGFRA PDGFRB
6 positive regulation of protein kinase B signaling GO:0051897 9.79 FGFR1 PDGFRA PDGFRB
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.77 ABL1 JAK2 PDGFRA
8 MAPK cascade GO:0000165 9.76 FGFR1 JAK2 PDGFRA PDGFRB
9 positive regulation of MAPK cascade GO:0043410 9.74 FGFR1 PDGFRA PDGFRB
10 phosphatidylinositol phosphorylation GO:0046854 9.72 FGFR1 PDGFRA PDGFRB
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 ABL1 PDGFRA PDGFRB
12 positive regulation of fibroblast proliferation GO:0048146 9.65 PDGFRA PDGFRB
13 response to retinoic acid GO:0032526 9.65 ASXL1 PDGFRB
14 thymus development GO:0048538 9.64 ABL1 ASXL1
15 skeletal system morphogenesis GO:0048705 9.64 FGFR1 PDGFRA
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.63 PDGFRA PDGFRB
17 cardiac myofibril assembly GO:0055003 9.61 PDGFRA PDGFRB
18 regulation of actin cytoskeleton reorganization GO:2000249 9.59 ABL1 PDGFRA
19 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.58 JAK2 PDGFRB
20 negative regulation of cell-cell adhesion GO:0022408 9.58 ABL1 JAK2
21 cell differentiation GO:0030154 9.56 ABL1 JAK2
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 FGFR1 JAK2 PDGFRA PDGFRB
23 peptidyl-tyrosine phosphorylation GO:0018108 9.55 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
24 retina vasculature development in camera-type eye GO:0061298 9.54 PDGFRA PDGFRB
25 phosphatidylinositol-mediated signaling GO:0048015 9.54 FGFR1 PDGFRA PDGFRB
26 positive regulation of phospholipase C activity GO:0010863 9.5 FGFR1 PDGFRA PDGFRB
27 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.48 ABL1 PDGFRB
28 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRA PDGFRB
29 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA PDGFRB
30 protein autophosphorylation GO:0046777 9.35 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
31 platelet-derived growth factor receptor signaling pathway GO:0048008 8.92 ABL1 JAK2 PDGFRA PDGFRB

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.92 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
2 kinase activity GO:0016301 9.8 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
3 nucleotide binding GO:0000166 9.76 FGFR1 JAK2 PDGFRA PDGFRB
4 protein kinase activity GO:0004672 9.55 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.54 ABL1 JAK2
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 FGFR1 PDGFRA PDGFRB
7 SH2 domain binding GO:0042169 9.51 ABL1 JAK2
8 phosphatidylinositol 3-kinase binding GO:0043548 9.49 JAK2 PDGFRB
9 platelet-derived growth factor receptor binding GO:0005161 9.48 PDGFRA PDGFRB
10 platelet-derived growth factor binding GO:0048407 9.43 PDGFRA PDGFRB
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR1 PDGFRA PDGFRB
12 vascular endothelial growth factor binding GO:0038085 9.32 PDGFRA PDGFRB
13 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 FGFR1 JAK2 PDGFRA PDGFRB
14 protein tyrosine kinase activity GO:0004713 9.02 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
15 protein binding GO:0005515 10.2 ABL1 ASXL1 CSF3R FGFR1 JAK2 PCM1

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....